# Intranasal Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intranasal-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Saddle Brook, US
- Website: www.ikanotherapeutics.com
- Total disclosed funding: $64M
- Latest round: Series B (Feb 11, 2009)
- Investors on record: 8

## About

Intranasal Therapeutics Inc. focuses on developing novel therapeutic solutions for medical conditions using advanced biologics and targeted therapies, particularly in oncology and autoimmune diseases.Intranasal Therapeutics Inc. is engaged in the innovative development of therapeutic solutions. The company is headquartered in Saddle Brook, US. On February 11, 2009, it raised USD 9 mn in a Series B funding round with participation from Burrill & Company, F-Prime Capital, SV Health Investors, and Tullis Health Investors. The founder has an extensive history in biotechnology and health investments, having established multiple companies in the sector.Intranasal Therapeutics specializes in innovative therapeutic solutions aimed at a variety of medical conditions. Its primary products include advanced biologics and targeted therapies designed to improve patient outcomes in oncology and autoimmune diseases. The company serves a diverse clientele, including hospitals and specialty clinics across North America and Europe, ensuring healthcare professionals have access to the latest advancements in treatment.Intranasal Therapeutics generates revenue through strategic partnerships and direct sales to healthcare institutions. The company employs a B2B model, collaborating with hospitals and clinics to supply its trademarked biologic products under multi-year contracts. Revenue is recognized upon product delivery, alongside maintenance and support services to ensure compliance with industry standards, fostering long-term relationships with clients.Intranasal Therapeutics plans to utilize the USD 9 mn raised in February 2009 to enhance its product development and expand its market reach. Upcoming new products are designed to address significant gaps in treatment, specifically targeting expansion into North America and Europe by the end of 2010. The recent funding will support these initiatives, aiming to introduce innovative therapies to healthcare providers and maintain competitive positioning in the market.

## Funding rounds

- Series B, Feb 11, 2009, $9M — Burrill & Company, Tullis Health Investors, SV Health Investors, F-Prime Capital
- Series B, Jun 4, 2008, $9M — Burrill & Company, Tullis Health Investors, Fletcher Spaght Ventures, SV Health Investors, F-Prime Capital
- Series A, Aug 15, 2006, $39M — Burrill & Company, Commonwealth Capital Ventures, Fort Washington Capital Partners, Tullis Health Investors, Apjohn Ventures, SV Health Investors, F-Prime Capital
- Series A, Aug 14, 2006, $7M — Burrill & Company, Fort Washington Capital Partners, Tullis Health Investors, Fletcher Spaght Ventures, Apjohn Ventures, SV Health Investors, F-Prime Capital

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A, Series B
- Fort Washington Capital Partners (https://capitalatlas.ai/funds/fort-washington-capital-partners) — Series A
- Tullis Health Investors (https://capitalatlas.ai/funds/tullis-health-investors) — Series A, Series B
- Fletcher Spaght Ventures (https://capitalatlas.ai/funds/fletcher-spaght-ventures) — Series A, Series B
- Apjohn Ventures (https://capitalatlas.ai/funds/apjohn-ventures) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Commonwealth Capital Ventures (https://capitalatlas.ai/funds/commonwealth-capital-ventures) — Series A